Freshpet, Inc. reported strong financial results for the fourth quarter and full year of 2024, showcasing significant growth across various metrics. For Q4, net sales rose 22% to $262.7 million, with ...

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 ...

Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 million ...